Suramin, as a drug for the treatment of trypanosomiasis, is considered to enhance the sensitivity of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains to existing antibiotics by inhibiting the SOS repair system mediated by the RecA protein of MTB (66). The gene discussed is RAD51; the disease is trypanosomiasis.